Circle's President Heath Tarbert sold $30.77 million in CRCL shares through 10 transactions since June 2025, with no buybacks recorded. This divestment coincides with CRCL's share price falling 17.5% to $62.63 from a post-IPO high near $260, driven by the launch of Open USD—a new stablecoin backed by major firms like Visa and Mastercard—posing a competitive threat. Analysts have lowered Circle's price target due to margin concerns, while Circle continues expanding regulatory approvals with the recent launch of Circle National Trust for digital asset custody. Despite challenges, Tarbert remains confident in Circle's long-term strategy and USDC's strong market position.
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...
Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...
Shares of Zhengye Biotechnology surged over 1047% to regain Nasdaq compliance after a minimum bid price warning. Advanced Biomed and Axe Compute also saw notable gains following a reverse stock split and Russell Microcap Index inclusion, respectively...
